Clinical Trial: SM-1 Combined With Temozolomide in Subjects With Refractory or Recurrent High-Grade Gliomas

U.S., June 10 -- ClinicalTrials.gov registry received information related to the study (NCT07635173) titled 'SM-1 Combined With Temozolomide in Subjects With Refractory or Recurrent High-Grade Gliomas' on May 05.

Brief Summary: The aim of this clinical trial is to evaluate the safety, preliminary effectiveness, and pharmacokinetic profiles of SM-1 (Obitrexate Fumarate Enteric-coated Pellet Capsules) combined with temozolomide, and conduct systematic dose exploration for the treatment of refractory or recurrent high-grade gliomas in adult patients. The core focus is to screen the optimal clinical dose regimen of SM-1, fully monitor adverse reactions, and preliminarily observe the anti-tumor efficacy of the combination regimen. The main ques...